A new review was published in Volume 16 of Oncotarget on June 17, 2025, titled "Optimizing enfortumab vedotin plus ...

However, enfortumab vedotin with or without pembrolizumab has been identified as a regimen of interest for these patients with upper tract urothelial cancer, explained Evangelia Vlachou, MD, a ...

And nearly half of responders to enfortumab vedotin plus pembrolizumab remained in remission. ... which really established this as a highly active regimen with a response rate that was in the 70% ...

-First regimen approved in advanced urothelial cancer to demonstrate superiority to platinum-containing chemotherapy, the standard of care for nea. Tuesday, 02 January 2024 12:17 GMT.

Among patients with upper tract urothelial carcinoma (UTUC) lesions, the combination of Padcev (enfortumab vedotin) and Keytruda (pembrolizumab) resulted in promising clinical activity, study results ...

Approval of KEYTRUDA plus enfortumab vedotin brings a potential new first-line standard of care to these patients in the European Union. RAHWAY, N.J., September 03, 2024--(BUSINESS WIRE)--Merck ...

- First regimen approved in advanced urothelial cancer to demonstrate superiority to platinum-containing chemotherapy, the standard of care for nearly 40 years1 - European Marketing Authorization ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the European Commission has granted Marketing Authorization for PADCEV™ (enfortumab vedotin ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the European Commission has granted Marketing Authorization for PADCEV™ (enfortumab vedotin, an ...